Literature DB >> 29051802

Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Ahmet Emre Eskazan1, Dilek Keskin2.   

Abstract

Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings. This review mainly focuses on the clinical potential of radotinib in patients with CML in chronic phase in terms of efficacy and safety.

Entities:  

Keywords:  bosutinib; chronic myeloid leukemia; dasatinib; imatinib; nilotinib; ponatinib; radotinib; tyrosine kinase inhibitor

Year:  2017        PMID： 29051802      PMCID： PMC5639974          DOI： 10.1177/2040620717719851

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  24 in total

Review 1.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

2.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Authors:  Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

Review 3.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

4.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Hagop M Kantarjian; Tim H Brümmendorf; Irina Dyagil; Laimonas Griskevicius; Hemant Malhotra; Christine Powell; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

5.  Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Authors:  Sung-Hyun Kim; Hari Menon; Saengsuree Jootar; Tapan Saikia; Jae-Yong Kwak; Sang-Kyun Sohn; Joon Seong Park; Seong Hyun Jeong; Hyeoung Joon Kim; Yeo-Kyeoung Kim; Suk Joong Oh; Hawk Kim; Dae Young Zang; Joo Seop Chung; Ho Jin Shin; Young Rok Do; Jeong-A Kim; Dae-Young Kim; Chul Won Choi; Sahee Park; Hye Lin Park; Gong Yeal Lee; Dae Jin Cho; Jae Soo Shin; Dong-Wook Kim
Journal:  Haematologica       Date:  2014-04-04       Impact factor: 9.941

6.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

8.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

9.  Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Authors:  M S Zabriskie; N A Vellore; K C Gantz; M W Deininger; T O'Hare
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

10.  Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Authors:  William V Padula; Richard A Larson; Stacie B Dusetzina; Jane F Apperley; Rudiger Hehlmann; Michele Baccarani; Ekkehard Eigendorff; Joelle Guilhot; Francois Guilhot; Rudiger Hehlmann; Francois-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Susanne Saussele; Charles A Schiffer; Richard T Silver; Bengt Simonsson; Rena M Conti
Journal:  J Natl Cancer Inst       Date:  2016-03-04       Impact factor: 13.506
View more
  7 in total

1.  Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2019-08-22       Impact factor: 4.335

Review 2.  Molecular targeted therapy for anticancer treatment.

Authors:  Hye-Young Min; Ho-Young Lee
Journal:  Exp Mol Med       Date:  2022-10-12       Impact factor: 12.153

Review 3.  Developing therapeutic approaches for chronic myeloid leukemia: a review.

Authors:  Veerandra Kumar; Malkhey Verma
Journal:  Mol Cell Biochem       Date:  2022-10-10       Impact factor: 3.842

Review 4.  Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Daru       Date:  2020-01-03       Impact factor: 3.117

Review 5.  Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy.

Authors:  Emanuela Andretta; Caterina Costa; Consiglia Longobardi; Sara Damiano; Antonio Giordano; Francesco Pagnini; Serena Montagnaro; Massimiliano Quintiliani; Chiara Lauritano; Roberto Ciarcia
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 6.  Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors:  Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Stem Cell Res Ther       Date:  2021-12-18       Impact factor: 6.832

Review 7.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.